![srdx core recognition srdx core recognition](https://i.pinimg.com/originals/8d/7d/4c/8d7d4cda2c8769a9a54f1c467c934188.jpg)
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.Įstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
![srdx core recognition srdx core recognition](https://i.ytimg.com/vi/ZRbJc6eWUUc/maxresdefault.jpg)
![srdx core recognition srdx core recognition](https://www.viatech.com/wp-content/uploads/2019/09/Facial-Recognition-1.jpg)
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Revenues are expected to be $23.83 million, up 6.9% from the year-ago quarter. This drug delivery technology company is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of -1900%. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. On the other hand, if they miss, the stock may move lower. The earnings report, which is expected to be released on February 3, 2022, might help the stock move higher if these key numbers are better than expectations. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. SurModics (SRDX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021.